Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Metformin for Antipsychotic-induced Weight Gain in Adults with Intellectual Disability Study: A Double-Blind Randomized Control Trial
EF 2025-26
Résumé
People with intellectual and developmental disabilities (IDD) often face serious health challenges, including very high rates of obesity and related conditions like diabetes. Many also have mental health disorders that require antipsychotic medications, which can cause significant weight gain and other metabolic problems. While diet and exercise programs can help, they often require skills and independence that may be difficult for this group. This means extra support, including medication, may be needed to manage weight. Metformin, a medication commonly used for diabetes, has shown promise in helping people lose weight and improve metabolic health, even when taking antipsychotics. Some studies in children and teens with autism suggest metformin can reduce antipsychotic-related weight gain, but there is very little research in adults with IDD. This group is often overlooked when it comes to obesity treatment. Therefore, to address this gap in the literature, the proposed randomized trial aims to study whether 24 weeks of treatment with metformin can lead to weight loss in people with obesity/overweight and IDD who are taking antipsychotics. The study will also explore changes to waist size, blood sugar control, and how well the medication is tolerated. A total of 100 participants, aged 16–65, will be randomly assigned to receive either metformin or placebo (inactive drug), along with healthy lifestyle advice. After the trial, participants will be offered to take metformin for another 24 weeks. Findings will inform on whether metformin is an effective treatment option for managing weight in this population. If successful, this could lead to better treatment guidelines and improve care for a group that faces major health risks but often gets little attention.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572984
Name
Mishra Soumya A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Metformin for Antipsychotic-induced Weight Gain in Adults with Intellectual Disability Study: A Double-Blind Randomized Control Trial
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Antipsychotic-Induced Weight Gain; Antipsychotics; Autism; Health Inequality; Intellectual And Developmental Disabilities; Metformin; Randomized Clinical Trial; Translational Medicine
Abstract
People with intellectual and developmental disabilities (IDD) often face serious health challenges, including very high rates of obesity and related conditions like diabetes. Many also have mental health disorders that require antipsychotic medications, which can cause significant weight gain and other metabolic problems. While diet and exercise programs can help, they often require skills and independence that may be difficult for this group. This means extra support, including medication, may be needed to manage weight. Metformin, a medication commonly used for diabetes, has shown promise in helping people lose weight and improve metabolic health, even when taking antipsychotics. Some studies in children and teens with autism suggest metformin can reduce antipsychotic-related weight gain, but there is very little research in adults with IDD. This group is often overlooked when it comes to obesity treatment. Therefore, to address this gap in the literature, the proposed randomized trial aims to study whether 24 weeks of treatment with metformin can lead to weight loss in people with obesity/overweight and IDD who are taking antipsychotics. The study will also explore changes to waist size, blood sugar control, and how well the medication is tolerated. A total of 100 participants, aged 16–65, will be randomly assigned to receive either metformin or placebo (inactive drug), along with healthy lifestyle advice. After the trial, participants will be offered to take metformin for another 24 weeks. Findings will inform on whether metformin is an effective treatment option for managing weight in this population. If successful, this could lead to better treatment guidelines and improve care for a group that faces major health risks but often gets little attention.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mishra, Soumya A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~